BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38640289)

  • 21. Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study.
    Eaden JA; Barber CM; Renshaw SA; Chaudhuri N; Bianchi SM
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):218-224. PubMed ID: 33093786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
    Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T
    Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis.
    Marcos Ribes B; Sancho-Chust JN; Talens A; Arlandis M; Herraiz P; Chiner E; Aznar T
    Eur J Hosp Pharm; 2020 Nov; 27(6):350-354. PubMed ID: 33020058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of efficacy and safety of pirfenidone 200 mg tablets in patients with idiopathic pulmonary fibrosis in a real-life setting.
    Coşkun F; Çilli A; Hanta İ; Sevinç C; Ödemiş A; Ursavaş A
    Turk J Med Sci; 2021 Dec; 51(6):3082-3088. PubMed ID: 34565135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena.
    Vietri L; Cameli P; Perruzza M; Cekorja B; Bergantini L; d'Alessandro M; Refini RM; Pieroni M; Fossi A; Bennett D; Spalletti M; Mazzei MA; Sestini P; Rottoli P; Bargagli E
    Ther Adv Respir Dis; 2020; 14():1753466620906326. PubMed ID: 32066332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety.
    Fernández Pérez ER; Crooks JL; Lynch DA; Humphries SM; Koelsch TL; Swigris JJ; Solomon JJ; Mohning MP; Groshong SD; Fier K
    Thorax; 2023 Nov; 78(11):1097-1104. PubMed ID: 37028940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis.
    Sakamoto S; Itoh T; Muramatsu Y; Satoh K; Ishida F; Sugino K; Isobe K; Homma S
    Intern Med; 2013; 52(22):2495-501. PubMed ID: 24240787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
    Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
    BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effectiveness, Safety, and Tolerability of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Retrospective Study.
    Hanta I; Cilli A; Sevinc C
    Adv Ther; 2019 May; 36(5):1126-1131. PubMed ID: 30900199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients.
    Chung MP; Park MS; Oh IJ; Lee HB; Kim YW; Park JS; Uh ST; Kim YS; Jegal Y; Song JW
    Adv Ther; 2020 May; 37(5):2303-2316. PubMed ID: 32297284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study.
    Sakamoto S; Muramatsu Y; Satoh K; Ishida F; Kikuchi N; Sano G; Sugino K; Isobe K; Takai Y; Homma S
    Respirology; 2015 Apr; 20(3):445-52. PubMed ID: 25639750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
    Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
    BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study.
    Lee EG; Lee TH; Hong Y; Ryoo J; Heo JW; Gil BM; Kang HS; Kwon SS; Kim YH
    PLoS One; 2021; 16(12):e0261684. PubMed ID: 34941933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
    Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
    Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes.
    Cottin V
    Eur Respir Rev; 2012 Jun; 21(124):161-7. PubMed ID: 22654089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case-control study.
    Ichimura T; Hinata M; Ichikura D; Suzuki S
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):21-30. PubMed ID: 34648059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies.
    Behr J; Nathan SD; Costabel U; Albera C; Wuyts WA; Glassberg MK; Haller H; Alvaro G; Gilberg F; Samara K; Lancaster L
    Adv Ther; 2023 Sep; 40(9):3937-3955. PubMed ID: 37391667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of lower dose pirfenidone for idiopathic pulmonary fibrosis in real practice: a retrospective cohort study.
    Hwang H; Lee JK; Choi SM; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Kim YW; Park JS
    Korean J Intern Med; 2022 Mar; 37(2):366-376. PubMed ID: 34293852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of pirfenidone in the treatment of interstitial pneumonia with autoimmune features.
    Chen T; Li QH; Zhang Y; Yin CS; Weng D; Zhou Y; Hu Y; Shi JY; Chen YN; Ye S; Wang XD; Wu CY; Huang Y; Zhang AH; Li HP
    Clin Exp Rheumatol; 2022 Mar; 40(3):560-567. PubMed ID: 33822701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.